1. Table of Contents
1.1 List of Tables
1.1 List of Tables

2. Executive Summary
2.1 Report Scope and Research Methodology
2.2 Introduction to Encephalitis Condition
2.3 Encephalitis Pipeline Snapshot, 2020
2.4 Companies investing in Encephalitis pipeline therapeutics
2.5 Phase wise Encephalitis Pipeline Candidates
2.6 Most Researched Mechanism of Action of Encephalitis Pipeline Products
2.7 Route of Administration of Encephalitis Pipeline Drugs

3. Companies Active in Pipeline Development
3.1 CEL-SCI Corp Overview, Contacts and ASD Pipeline Drugs
3.2 Cerion LLC Overview, Contacts and ASD Pipeline Drugs
3.3 Cour Pharmaceutical Development Company Inc Overview, Contacts and ASD Pipeline Drugs
3.4 F. Hoffmann-La Roche Ltd Overview, Contacts and ASD Pipeline Drugs
3.5 Knight Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.6 NeurMedix Inc Overview, Contacts and ASD Pipeline Drugs
3.7 Olymvax Biopharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
3.8 Sage Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs

4. Active Pipeline Drug Details, 2020
4.1 CEL-1000 Drug Details
4.1.1 CEL-1000 Current Status
4.1.2 CEL-1000 Drug Overview
4.1.3 CEL-1000 Mechanism of Action
4.1.4 CEL-1000 Licensing/Collaboration Companies
4.1.5 CEL-1000 Clinical Trials

4.2 Cerium dioxide Drug Details
4.2.1 Cerium dioxide Current Status
4.2.2 Cerium dioxide Drug Overview
4.2.3 Cerium dioxide Mechanism of Action
4.2.4 Cerium dioxide Licensing/Collaboration Companies
4.2.5 Cerium dioxide Clinical Trials

4.3 Immune modifying particle (IMP) technology for Encephalitis Drug Details
4.3.1 Immune modifying particle (IMP) technology for Encephalitis Current Status
4.3.2 Immune modifying particle (IMP) technology for Encephalitis Drug Overview
4.3.3 Immune modifying particle (IMP) technology for Encephalitis Mechanism of Action
4.3.4 Immune modifying particle (IMP) technology for Encephalitis Licensing/Collaboration Companies
4.3.5 Immune modifying particle (IMP) technology for Encephalitis Clinical Trials

4.4 ocrelizumab Drug Details
4.4.1 ocrelizumab Current Status
4.4.2 ocrelizumab Drug Overview
4.4.3 ocrelizumab Mechanism of Action
4.4.4 ocrelizumab Licensing/Collaboration Companies
4.4.5 ocrelizumab Clinical Trials

4.5 miltefosine Drug Details
4.5.1 miltefosine Current Status
4.5.2 miltefosine Drug Overview
4.5.3 miltefosine Mechanism of Action
4.5.4 miltefosine Licensing/Collaboration Companies
4.5.5 miltefosine Clinical Trials

4.6 NE3413 Drug Details
4.6.1 NE3413 Current Status
4.6.2 NE3413 Drug Overview
4.6.3 NE3413 Mechanism of Action
4.6.4 NE3413 Licensing/Collaboration Companies
4.6.5 NE3413 Clinical Trials

4.7 13-valent pneumococcal vaccine Drug Details
4.7.1 13-valent pneumococcal vaccine Current Status
4.7.2 13-valent pneumococcal vaccine Drug Overview
4.7.3 13-valent pneumococcal vaccine Mechanism of Action
4.7.4 13-valent pneumococcal vaccine Licensing/Collaboration Companies
4.7.5 13-valent pneumococcal vaccine Clinical Trials

4.8 23-valent pneumococcal vaccine Drug Details
4.8.1 23-valent pneumococcal vaccine Current Status
4.8.2 23-valent pneumococcal vaccine Drug Overview
4.8.3 23-valent pneumococcal vaccine Mechanism of Action
4.8.4 23-valent pneumococcal vaccine Licensing/Collaboration Companies
4.8.5 23-valent pneumococcal vaccine Clinical Trials

4.9 SAGE-718 Drug Details
4.9.1 SAGE-718 Current Status
4.9.2 SAGE-718 Drug Overview
4.9.3 SAGE-718 Mechanism of Action
4.9.4 SAGE-718 Licensing/Collaboration Companies
4.9.5 SAGE-718 Clinical Trials

5. Latest Encephalitis Pipeline News and Deals

6. Appendix
6.1 Our Databases and Reports
6.2 Research Methodolgy

Companies mentioned
CEL-SCI Corp, Cerion LLC, Cour Pharmaceutical Development Company Inc, F. Hoffmann-La Roche Ltd, Knight Therapeutics Inc, NeurMedix Inc, Olymvax Biopharmaceuticals Inc, Sage Therapeutics Inc